Company: TXG
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001770787-25-000013
Chunk: 3

Company: 10x Genomics, Inc.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 8
Chunk 3
---
2 2 Additional paid-in capital2,177,672 2,025,890 Accumulated deficit(1,467,047)(1,284,420)Accumulated other comprehensive loss(493)(429)Total stockholders’ equity710,134 741,043 Total liabilities and stockholders’ equity$918,636 $965,143 

The accompanying notes are an integral part of these consolidated financial statements.

79

10x Genomics, Inc.

Consolidated Statements of Operations

(In thousands, except share and per share data)

Year Ended December 31,202420232022Revenue$610,785 $618,727 $516,409 Cost of revenue196,303 209,414 120,386 Gross profit414,482 409,313 396,023 Operating expenses:Research and development264,698 270,332 265,667 In-process research and development— 60,980 — Selling, general and administrative344,343 343,330 298,300 Total operating expenses609,041 674,642 563,967 Loss from operations(194,559)(265,329)(167,944)Other income (expense):Interest income18,448 16,906 6,647 Interest expense(4)(33)(476)Other expense, net(1,585)(307)(198)Total other income16,859 16,566 5,973 Loss before provision for income taxes(177,700)(248,763)(161,971)Provision for income taxes4,927 6,336 4,029 Net loss$(182,627)$(255,099)$(166,000)Net loss per share, basic and diluted$(1.52)$(2.18)$(1.46)Weighted-average shares used to compute net loss per share, basic and diluted120,451,550 117,165,036 113,858,684 

The accompanying notes are an integral part of these consolidated financial statements.

80

10x Genomics, Inc.

Consolidated Statements of Comprehensive Loss

(In thousands)

December 31,202420232022Net loss$(182,627)$(255,099)$(166,000)Other comprehensive income (loss), net of tax:Unrealized gains (losses) on available-for-sale marketable securities206 2,210 (4,